← Oncology Approval Tracker

FDA DECISION ·

Enhertu

fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant treatment for adults with HER2-positive breast cancer (IHC 3+ or ISH-positive) and residual invasive disease after neoadjuvant trastuzumab with or without pertuzumab and a taxane-based regimen.

LAMPGEN ANALYSIS

Why it matters

DESTINY-Breast05 tested an ADC against T-DM1 in residual disease after neoadjuvant therapy. That post-surgery risk population differs from the newly approved presurgery indication.

What research teams should watch

Reconcile the neoadjuvant regimen with residual invasive disease on surgical pathology. Build a clear process for monitoring and escalating potential ILD or pneumonitis.

PRIMARY RECORDS

Sources